Catherine R. Judd, MS, PA-C
Dept of Psychiatry, Psychoneuroendocrine Group
University of Texas Southwestern Medical Center
Thomas Roth, PhD
Chief, Division Head
Sleep Disorders and Research Center
Henry Ford Hospital
CME CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIAN ASSISTANTS ONLY.
This "Virtual Meeting" program was originally presented on May 29, 2005 as an adjunct symposium at the 2005 AAPA Annual Conference in Orlando, FL.
Insomnia is defined as difficulty initiating or maintaining sleep or a complaint of nonrestorative sleep. The condition is a common problem that can affect almost anyone from time to time. Acute/transient insomnia, lasting 1 to 3 nights, affects approximately 30%-40% of adults in a given year. Around 10% of all primary care patients experience chronic insomnia that lasts for more than 3 nights per week for 1 month or more.
Some of the consequences of insomnia include impaired cognitive function, increased risk of psychiatric disorders, decreased job performance and productivity, and decreased quality of life. In addition, people with insomnia have 50% higher healthcare costs than those without the condition.
This program examines normal sleep modulation and risk factors, prevalence, and the consequences of insomnia. It reviews recommended pharmacological and behavioral treatment plans, including the latest pharmacological inrterventions.
. Target Audience
Physician assistants with an interest in the management of insomnia.
Upon completion of this educational activity, the participant should be able to:
Discuss the prevalence, risk factors, and consequences of insomnia
Review circadian and homeostatic mechanisms that control sleep
Evaluate the patient who complains of insomnia
Develop appropriate treatment plans that encompass behavioral and pharmacologic intervention
Thomas Roth, PhD discloses that he has received grants from sanofi-aventis, Cephalon, Inc., GlaxoSmithKline, Neurocrine Biosciences, Pfizer Inc, Sepracor Inc., Somaxon Pharmaceuticals, Syrex and Takeda Pharmaceuticals America, Inc. He is a consultant for AstraZeneca, Cephalon, Inc., Cypress Pharmaceutical, Inc., Eli Lilly and Company, GlaxoSmithKline, Hypnion, Inc., King Pharmaceuticals, Lundbeck Pharmaceuticals, McNeil Consumer & Speciality Pharmaceuticals, Neurocrine Biosciences, Organon Inc., Orginer, Pfizer Inc, Roche Pharmaceuticals, sanofi-aventis, Sepracor Inc., Somaxon Pharmaceuticals, Syrex, Takeda Pharmaceuticals America, Inc. TransOral Pharmaceuticals, Inc., VivoMetrics, Inc., and Wyeth Pharmaceuticals. He is also a speaker for sanofi-aventis.
Dr. Roth will be discussing off-label, unapproved and/or investigational uses in this presentation.
Catherine R. Judd, MS, PA-C discloses that she has no significant financial interest or other relationship with the manufacturer of any commercial product or service discussed in this educational presentation or with the commercial supporter of this activity.
This program has been reviewed and is approved for a maximum of 1.25 hours of clinical Category I (Preapproved) CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of August 1, 2005. Participants may submit the self-assessment at any time during that period.
This program was planned in accordance with AAPA’s CME Standards for Enduring Materials Programs and for Commercial Support of Enduring Materials Programs.
Commercial Support Statements
This activity is supported by an educational grant from Takeda Pharmaceuticals North America.
Turn off any pop-up blockers which might be running on your computer.
Clicking on "start the program" on this screen will bring you to program-specific instructions and a menu screen from which you can select the presentations you wish to view. Complete all available presentations to qualify for credit. The program will take approximately 75 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. PAs who are members of the AAPA will be able to complete an online post-test at no charge. PAs who are not AAPA members will be able to print an answer sheet which must be submitted to AAPA with a $20 scoring fee.
A minimum score of 70% on the post-test is required for a CME certificate.
Click on the "Start program" icon.
The next screen will permit you to check for or download the Flash player required to run this program.
Physician assistants who are not members of the AAPA are required to submit a $20 scoring fee to the AAPA.
© 2005, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AAPA, or Takeda Pharmaceuticals North America. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.